Targeting CD30 in anaplastic large cell lymphoma.
Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by strong and uniform expression of the CD30 antigen on the cell surface. Current standard frontline therapy of ALCL is anthracycline-based combination chemotherapy, usually CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOP-like regimens. Despite aggressive chemotherapy a significant number of patients relapse. Newer agents and strategies are needed in the management of this challenging disease especially in ALK-negative and high-risk ALK-positive patients who tend to have a poor prognosis. In this review we discuss the different approaches to targeting CD30 including naked antibodies, "enhanced antibodies", antibody drug-toxin conjugates, radioimmunoconjugates, CD30-ligand-toxin conjugates, bispecific antibodies and T cell-based immune therapies.
Fox Chase Cancer Center, Philadelphia, PA, USA.
Joseph
J
Vadakara
Barbara
B
Pro
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017728:Lymphoma, Large-Cell, Anaplastic / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen